SG25195G - Hybrid interferons - Google Patents

Hybrid interferons

Info

Publication number
SG25195G
SG25195G SG25195A SG25195A SG25195G SG 25195 G SG25195 G SG 25195G SG 25195 A SG25195 A SG 25195A SG 25195 A SG25195 A SG 25195A SG 25195 G SG25195 G SG 25195G
Authority
SG
Singapore
Prior art keywords
interferons
hybrid interferons
novel hybrid
hybrid
interferon
Prior art date
Application number
SG25195A
Other languages
English (en)
Inventor
Albert Dr Hinnen
Andreas Dr Meister
Markus Gerhard Dr Gruetter
Sefik Prof Dr Alkan
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Application filed by Ciba Geigy filed Critical Ciba Geigy
Priority to SG25195A priority Critical patent/SG25195G/en
Publication of SG25195G publication Critical patent/SG25195G/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG25195A 1985-06-11 1995-02-16 Hybrid interferons SG25195G (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG25195A SG25195G (en) 1985-06-11 1995-02-16 Hybrid interferons

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
SG25195A SG25195G (en) 1985-06-11 1995-02-16 Hybrid interferons

Publications (1)

Publication Number Publication Date
SG25195G true SG25195G (en) 1995-08-18

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
SG25195A SG25195G (en) 1985-06-11 1995-02-16 Hybrid interferons

Country Status (20)

Country Link
US (2) US4885166A (da)
EP (1) EP0205404B1 (da)
JP (2) JPH0655759B2 (da)
KR (1) KR920002267B1 (da)
AT (1) ATE78262T1 (da)
AU (1) AU598196B2 (da)
CA (1) CA1285507C (da)
CY (1) CY1842A (da)
DE (1) DE3685996T2 (da)
DK (1) DK168794B1 (da)
FI (1) FI90983C (da)
GR (1) GR861497B (da)
HK (1) HK99895A (da)
HU (1) HU203255B (da)
IE (1) IE57865B1 (da)
IL (1) IL79085A (da)
NO (1) NO175602C (da)
NZ (1) NZ216485A (da)
PT (1) PT82736B (da)
SG (1) SG25195G (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
AU651152B2 (en) * 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
ATE157703T1 (de) * 1991-12-16 1997-09-15 Ciba Geigy Ag Endoplasmatisches retikulum-ständige rekombinante dibasische endoprotease und deren verwendungen
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
DE69323131T2 (de) * 1992-03-10 1999-09-16 La Jolla Cancer Research Foundation, La Jolla Rekombinierte alkalische phosphatase aus kälberdarm
TW218846B (da) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (da) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
WO1996024678A1 (en) 1995-02-09 1996-08-15 Novartis Ag Process for the production of proteins
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
LT2599503T (lt) 1998-10-16 2017-06-26 Biogen Ma Inc. Interferono beta-1a polimero konjugatai ir jų panaudojimas
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
AU2587002A (en) * 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
EP1536839B1 (en) * 2001-11-09 2010-09-15 Intarcia Therapeutics, Inc Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
AU2003297285A1 (en) * 2002-11-18 2004-06-15 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
TW200611910A (en) * 2004-05-19 2006-04-16 Maxygen Inc Interferon-alpha polypeptides and conjugates
JP2008509889A (ja) * 2004-06-30 2008-04-03 イージェン コーポレーション ペグ化インターフェロンα−１ｂ
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CA2607651A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
EP2041259B1 (en) 2006-07-14 2015-10-14 DPx Holdings B.V. Improved process for the culturing of cells
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
BRPI0720035A2 (pt) 2006-12-06 2019-05-07 Medimmune, Llc métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
NZ580686A (en) * 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
JP5411129B2 (ja) 2007-05-03 2014-02-12 メディミューン，エルエルシー インターフェロンα誘導性薬力学的マーカー
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009061818A1 (en) 2007-11-05 2009-05-14 Medimmune, Llc Methods of treating scleroderma
ES2529593T3 (es) 2008-02-08 2015-02-23 Medimmune, Llc Marcadores de enfermedades y usos de los mismos
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR20120101340A (ko) 2009-09-03 2012-09-13 메디뮨 엘엘씨 1형 인터페론 진단
KR102148624B1 (ko) 2009-09-28 2020-08-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR102050339B1 (ko) 2011-03-15 2019-11-29 바이오젠 엠에이 인코포레이티드 빠른 적정 단계식 증가 투여 요법을 이용한 인터페론의 근육내 투여와 관련된 독감 유사 증상의 감소 방법
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
JP7522749B2 (ja) 2019-02-15 2024-07-25 アストラゼネカ・アクチエボラーグ Ｉ型インターフェロン媒介性障害
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO164037C (no) * 1980-01-08 1990-08-22 Biogen Inc Fremgangsmaate ved fremstilling av et polypeptid av interferon alfa (ifnalfa)-type.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
WO1983002461A1 (en) * 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons

Also Published As

Publication number Publication date
DE3685996D1 (de) 1992-08-20
FI90983C (fi) 1994-04-25
HU203255B (en) 1991-06-28
NO175602C (no) 1994-11-02
PT82736A (en) 1986-07-01
NZ216485A (en) 1991-06-25
EP0205404B1 (en) 1992-07-15
FI862461A0 (fi) 1986-06-09
HK99895A (en) 1995-06-30
JPH0736757B2 (ja) 1995-04-26
JPH05308973A (ja) 1993-11-22
JPS626000A (ja) 1987-01-12
US4885166A (en) 1989-12-05
DK168794B1 (da) 1994-06-13
DK272986D0 (da) 1986-06-10
NO862313L (no) 1986-12-12
CA1285507C (en) 1991-07-02
EP0205404A3 (en) 1987-10-21
NO175602B (no) 1994-07-25
IL79085A0 (en) 1986-09-30
FI862461A (fi) 1986-12-12
US5071761A (en) 1991-12-10
AU5849986A (en) 1986-12-18
DK272986A (da) 1986-12-12
NO862313D0 (no) 1986-06-10
PT82736B (pt) 1988-12-15
IE861542L (en) 1986-12-11
CY1842A (en) 1996-03-08
EP0205404A2 (en) 1986-12-17
FI90983B (fi) 1994-01-14
IL79085A (en) 1992-03-29
IE57865B1 (en) 1993-05-05
HUT41846A (en) 1987-05-28
DE3685996T2 (de) 1993-01-14
JPH0655759B2 (ja) 1994-07-27
GR861497B (en) 1986-10-10
AU598196B2 (en) 1990-06-21
KR920002267B1 (ko) 1992-03-20
ATE78262T1 (de) 1992-08-15
KR870000427A (ko) 1987-02-18

Similar Documents

Publication Publication Date Title
EP0205404A3 (en) Hybrid interferons
DE3583521D1 (de) Antivirale verbindungen.
AU2964489A (en) Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides
ES8500996A1 (es) Meotod de producir un polipeptido.
EP0263072A3 (en) Novel lymphokine related peptides
IE822385L (en) Recombinant dna's coding for interferon polypeptides
FI850275L (fi) Nya 6-susbtituerade furo-(3,4-c) -pyridinderivat.
ES8609475A1 (es) Procedimiento para preparar peptidos de interferon
NZ228105A (en) Antihypertensive hyperimmune milk, its production and medicaments therefrom
EP0315637A4 (en) POLYPEPTIDES USEFUL IN THE DIAGNOSIS OF MYCOPLASMA INFECTIONS IN PIGS, AND RECOMBINANT DNA METHODS FOR THEIR MANUFACTURE.
AU598460B2 (en) Process preparing and purifying interferon
ES8404373A1 (es) Un procedimiento para obtener compuestos de ribofuranosilselenazol-4-carboxamida.
AU4970885A (en) Novel lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses
ES2001108A6 (es) Un procedimiento para la preparacion de un derivado de gem-dihalo-1,8-diamino -4 -aza-octano.
EP0276120A3 (en) Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
SU939352A1 (ru) Двухмассный вибрационный конвейер